2020-09-27@22:51:46 GMT
28 results - (0.000 seconds)

AstraZeneca and:

    mAbxience, from Grupo Insud, will manufacture the active substance of the vaccine, which will be packaged in Mexico. We tell you why they chose it Until President Alberto Fernández appointed him, very few Argentines had heard of mAbxience, the biotechnology company that, as the president announced, will be in charge of producing the Oxford vaccine for Latin America. However, this laboratory, which is dedicated to producing drugs for oncological and autoimmune diseases, seems to have been tailor-made to meet this challenge. mAbxience is not only dedicated to something similar, but it has a unique advantage: last February, just before the arrival of the coronavirus in Argentina, it had opened a massive new state-of-the-art plant on...
    US regulators are 'very concerned' about the potential side effects of AstraZeneca and Oxford University's coronavirus vaccine and are debating whether or not to allow the trials to resume. Last week, the trial was put on hold when a British participant was rushed to the hospital after suffering a serious reaction that triggered spinal cord inflammation.  On Saturday, the drugmaker announced that trials for the vaccine would continue in the UK, but the America arm has not restarted.  The hold will remain while the US Food and Drug Administration (FDA) conducts an independent investigation as well as the National Institutes of Health (NIH).  US regulators say they are 'very concerned' about AstraZeneca and Oxford University's coronavirus vaccine after the...
    London — Oxford University announced over the weekend that it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca. The move came less than a week after the study was suspended following a reported possible side-effect in a U.K. patient. In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday. "The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.," it said. Get Breaking News Delivered to Your Inbox The vaccine being developed by Oxford and AstraZeneca...
    LONDON (AP) — Oxford University announced Saturday it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca, a move that comes days after the study was suspended following a reported side-effect in a U.K. patient. In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday. “The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,” it said. The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of the strongest contenders among the...
    By Pan Pylas | Associated Press LONDON — Oxford University announced Saturday it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca, a move that comes days after the study was suspended following a reported side-effect in a U.K. patient. In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday. “The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,” it said. The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of the...
    Trials of Oxford University's coronavirus vaccine could be allowed to restart just days after a British volunteer was rushed to hospital with suspected swelling in their spinal cord. UK drug giant AstraZeneca, which owns the rights to the vaccine, announced that all studies of the jab had been paused indefinitely while it investigates whether the patient's side-effect is connected to the vaccine. It is understood the female volunteer showed symptoms of transverse myelitis (TM), a rare inflammatory condition that affects the spinal cord. This means no one else will be given the vaccine until the investigation has been completed. However, health industry website Stat reported that a woman was suspected to have TM but the diagnosis was not confirmed, and she...
    Dr Anthony Fauci set himself at odds with Donald Trump yet again by sharing his disapproval of the president's crowded campaign rallies where hundreds of supporters gather without masks or social distancing.   Fauci, the nation's leading infection disease expert and a member of the White House coronavirus task force, addressed the issue in an interview with CBS This Morning on Wednesday, hours after a massive MAGA rally in North Carolina.  Asked if he was frustrated by scenes showing supporters - and Trump himself - not wearing masks, Fauci said: 'Well, yes, it is. I've said that often. 'We want to set an example because we know that when you do four or five typical kind of public health measures -...
    LONDON (Reuters) - AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, denting the British drugmaker's shares as the move was seen as dimming prospects for an early rollout. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials," AstraZeneca said in an emailed statement. Below are reactions from scientists, drugmakers and stock market traders and analysts to the news: SCIENTISTS: Ian Jones, Professor of Virology at the University of Reading: "An inevitable consequence of testing a vaccine on large numbers of people is that some will naturally fall ill of other causes during the trial. We must wait and see...
    Phase 3 trials for the coronavirus vaccine being developed by Oxford University and AstraZeneca have been placed on a hold after a 'serious adverse event' was reported in a participant in the UK, according to Stat News.  Serious adverse events are suspected reactions to vaccines or drugs that require hospitalization, are life-threateningly or deadly.  It's unclear what the exact nature of the reaction was, but a person familiar with the matter told Stat News that the person is expected to recover.  Trial holds are not uncommon, but it is a blow to worldwide hopes for a shot to be ready in the coming months, as the AstraZeneca shot was considered by many - including the World Health Organization - to...
    The world may be one step closer to getting a coronavirus jab after Oxford University's vaccine candidate entered its final stage of tests in the US. UK drug giant AstraZeneca, which owns the rights to the vaccine, said it had enrolled 30,000 American volunteers to take part in its phase three clinical trial. It now means 50,000 people worldwide are taking part in studies to see whether the jab - known as AZD1222 - can actually prevent people getting infected with Covid-19. Thousands of volunteers have already been injected with the experimental drug in the UK, Brazil and South Africa and are being monitored by scientists. Oxford's Professor Sarah Gilbert, the brains behind the jab, said preliminary data from trials in these countries...
    Governments and companies are investing large amounts of money in research to achieve the Covid-19 immunization. Despite the fact that all of them have assured that the vaccine will not be a business, the price difference between them is very significant: while that of Oxford and AstraZeneca will cost between $ 3 and $ 4, Sinopharm It amounts to more than one hundred euros. For now, there are four vaccine candidates (Sinopharm, Modern, Pfizer and Oxford and AstraZeneca) found in the Phase 3, in which clinical trials are carried out in humans in order to verify its safety and efficacy. The President of National Biotec Group, Liu Jingzhen, a state company that is part of Sinopharm, has announced that its...
    COVID-19 vaccine, and with the “impatient” wait for the WHO to analyze the results of its clinical tests, this Wednesday, August 12, it emerged that Mexico and Argentina will contribute to the production of the AstraZeneca vaccine for Latin America. “data-reactid =” 12 “> After Russia became the first country to grant regulatory approval to a vaccine against COVID-19, and with the” impatient “wait for the WHO to analyze the results of its clinical tests, this Wednesday, August 12, it transpired that Mexico and Argentina will contribute to the production of the AstraZeneca vaccine for Latin America. “The laboratory (AstraZeneca) has signed an agreement with the Carlos Slim Foundation (Mexico) to produce between 150 and 250 million vaccines destined for...
    AstraZeneca and Johnson & Johnson promised to offer their coronavirus vaccines to the US at cost during testimony before a Congressional committee on Tuesday. UK-based Astrazeneca also said that it would ramp up production of its prospective vaccine - created with Oxford University - to ensure that 300 million doses are available to the US immediately upon its hopeful Food and Drug Administration (FDA) approval.  Spokespeople for Moderna, Pfizer, Johnson & Johnson, and Merck all admitted that they intended to profit on the COVID-19 vaccines they are developing, although Johnson & Johnson (J&J) said it would provide its shot at-cost for the duration of the national emergency.   Questioning during the hearing focused largely on the accessibility, supply chain and safety...
    A coronavirus vaccine candidate developed by Oxford University in the United Kingdom with pharmaceutical giant AstraZeneca has shown potential in preliminary trials. Early human trials found that the vaccine candidate appears to be safe and induced an immune response to infection in all 1,077 volunteers, according to findings published Monday in the medical journal the Lancet. Researchers from Oxford University and AstraZeneca found that the vaccine generated antibodies and killer T-cells that attack virus cells. The team was not able to conclude whether the vaccine would prevent COVID-19 infection, however. Efficacy trials have not been completed. The research team also found that side effects were minimal. The two most common effects were headache and fatigue. Members of...
    The early results of Oxford University and AstraZeneca’s coronavirus vaccine trial are expected imminently, according to media reports. The BBC reports that the early-stage trial data will be released Monday. Citing people involved in the trial, the Daily Telegraph reported last week that the vaccine could offer a “double defense” against the virus, provoking both a T-cell response and an antibody response. The Telegraph also reports that data on the trial will be released Monday. UK CORONAVIRUS VACCINE TRIAL IS 'PROGRESSING VERY WELL,' RECRUITING CHILDREN AND OLDER ADULTS Fox News has reached out to Oxford University and AstraZeneca with a request for comment on this story. AstraZeneca shares were up slightly more than 1 percent to $61.75 in pre-market trading....
    By Marcelo Rochabrun SAO PAULO (Reuters) - Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic. The AstraZeneca vaccine is considered the world's leading candidate and most advanced in terms of development to obtain licensure and become an official vaccine against the disease, according to the World Health Organization. The British drugmaker is already carrying out large-scale, mid-stage human trials of the vaccine, which was developed by researchers at Oxford University. Elcio Franco, Brazil's No.2 public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by...
    White House coronavirus advisor Dr. Anthony Fauci, along with three other top U.S. health officials, are slated to answer questions from members of Congress about the national response to the pandemic on Tuesday. Top officials from the Centers for Disease Control and Prevention, the Food and Drug Administration and the Department of Health and Human Services are expected to testify about what each agency has done in response to the coronavirus outbreak.   This is CNBC's live blog covering all the latest news on the coronavirus outbreak. This blog will be updated throughout the day as the news breaks.  Global cases: More than 9.11 million Global deaths: At least 472,541 U.S. cases: More than 2.31 million U.S. deaths: At least 120,402...
    LONDON (AP) - Pharma giant AstraZeneca struck a deal Saturday with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of an experimental COVID-19 vaccine, as efforts to boost manufacturing capacity continue at pace. The alliance, which was forged by Germany, France, Italy and the Netherlands to speed up production of a vaccine, is set to take delivery of the vaccine being tested by the University of Oxford by the end of 2020. The agreement with AstraZeneca also aims to make the vaccine available to other European countries that wish to take part. The cost is expected to be offset by funding from the governments. TOP STORIES Four St. Louis police officers charged with beating undercover colleague Trump...
    AstraZeneca has approached Gilead Sciences about a massive merger that would combine two companies leading the pharmaceutical industry’s battle against the coronavirus, a report says. The British drugmaker reached out to California-based Gilead last month about whether it would be interested in merging, Bloomberg News reported Sunday. But there are no formal talks and Gilead is not currently interested in merging with another large firm, the story said, citing unnamed people familiar with the matter. The tie-up would be the health care industry’s largest ever, according to Bloomberg. AstraZeneca was worth about $140 billion as of Friday, while Gilead had a market value of roughly $96 billion. An AstraZeneca spokesman said the company does not comment on rumors or speculation....
    London (CNN Business)AstraZeneca has approached rival drugmaker Gilead about a potential merger, according to a Bloomberg report. Neither company responded to requests for comment on Monday, but if the transaction were to take place, it would unite two of the leading players in the fight against coronavirus in the biggest health care deal on record.AstraZeneca has secured production capacity to make 2 billion doses of a potential vaccine, while the experimental Gilead drug remdesivir has been approved by the US government to treat hospitalized patients with severe Covid-19.Shares in AstraZeneca (AZN) dropped by more than 2% in London even as the FTSE 100 (UKX) index rose after Bloomberg reported the UK-based company made a preliminary approach last month to US...
    London (CNN Business)AstraZeneca says it has secured capacity to produce 2 billion doses of a potential coronavirus vaccine being developed in partnership with researchers at Oxford University.The new production figure includes 400 million doses that will be provided to low and middle-income countries before the end of this year.Modernas coronavirus vaccine announcement set off a frenzy on Wall Street. Now some are calling for an investigationThe UK-based pharmaceutical company announced Thursday that it had signed two additional deals involving the vaccine, which is currently being tested in about 10,000 adult volunteers in Britain.AstraZeneca (AZN) has agreed a $750 million deal to produce 300 million doses with international foundations the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance. A...
    British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in a handful of deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower-income countries. The deals with epidemic response group CEPI and vaccine alliance GAVI are backed by the World Health Organization and aim to quell concerns that the company was committing all initial supplies of the vaccine to the developed world. It is unclear if vaccines will work against the coronavirus but dozens of companies are in the race to develop one, and AstraZeneca’s partnership with Oxford University is one of a handful to be backed so far by the US COVID task force. The White House last month secured...